 |
 |
 |
 |
 |
 |
||
 |
 |
 |
 |
 |
| 1 | 1/1 | 返回列表 |
| 查看: 360 | 回復(fù): 0 | |||
ienjoysun銀蟲(chóng) (著名寫手)
|
[交流]
Horizon Pharma to acquire Vidara Therapeutics for around $660 million
|
|
Horizon Pharma to acquire Vidara Therapeutics for around $660 million (Ref: The Wall Street Journal, NASDAQ, Marketwired, Yahoo!Finance, StreetInsider, The Irish Times) March 19th, 2014 By: Joe Barber Tags: Top Story Actimmune Duexis Lodotra Rayos Vimovo Horizon Pharma Vidara Corporate Affairs Mergers & Acquisitions Horizon Pharma entered a definitive agreement to buy Vidara Therapeutics through a reverse stock-and-cash merger valued at approximately $660 million, the companies announced Wednesday. The transaction is aimed at helping Horizon transform to a profitable specialty pharmaceutical company, with CEO Timothy Walbert noting the merger gives it "a portfolio of four proprietary products and an international platform that builds on our strategy of organic growth and acquisitions." Under the terms of the agreement, the combined drugmaker will operate under the Horizon Pharma name and be organised under Irish laws. Current stockholders of Horizon would own approximately 74 percent of the merged entity, while Vidara shareholders would hold about 26 percent and receive $200 million in cash. Further, Horizon's current officers will become officers of the combined company, including Walbert as president and CEO, with Vidara executives given "important leadership and management roles." The deal will give Horizon rights to Vidara's biologic response modifier Actimmune (interferon gamma-1b). The therapy, which recorded sales of $58.9 million in 2013, is cleared in the US to treat chronic granulomatous disease and severe malignant osteopetrosis in children and adults. "The addition of Actimmune complements our commercial business model focused on targeted promotion to primary care physicians and specialists," Walbert said. In addition to Actimmune, the expanded revenue base would also include Horizon's current products, namely the anti-inflammatory drugs Duexis (famotidine/ibuprofen) and Vimovo (naproxen/esomeprazole), both of which are marketed in the US, as well as Rayos (prednisone) and its counterpart Lodotra, which are sold inside and outside the US, respectively. The proposed acquisition, which the boards of both companies unanimously approved, is expected to close mid-year pending approval by Horizon shareholders. The companies estimate that the merger will result in combined revenues of $250 million to $265 million for 2014, with earnings between $65 million and $75 million, excluding certain one-time transaction expenses. |
回復(fù)此樓» 猜你喜歡
南方醫(yī)科大學(xué)珠江醫(yī)院肖計(jì)生課題組招收博士生 （2026年入學(xué)）
已經(jīng)有2人回復(fù)
-
349藥學(xué)專碩105500求調(diào)劑
已經(jīng)有0人回復(fù)
-
藥理學(xué)論文潤(rùn)色/翻譯怎么收費(fèi)?
已經(jīng)有195人回復(fù)
-
求調(diào)劑
已經(jīng)有1人回復(fù)
-
298求調(diào)劑一志愿中海洋
已經(jīng)有3人回復(fù)
-
藥學(xué)調(diào)劑申請(qǐng)自薦信，一志愿中南大學(xué)
已經(jīng)有1人回復(fù)
-
藥學(xué)349專碩求調(diào)劑
已經(jīng)有1人回復(fù)
-
錦州醫(yī)科大學(xué)藥用生物材料（專業(yè)代碼1007Z1）招收調(diào)劑考生
已經(jīng)有0人回復(fù)
-
錦州醫(yī)科大學(xué)藥用生物材料（專業(yè)代碼1007Z1）招收調(diào)劑考生
已經(jīng)有2人回復(fù)
-
《左乙拉西坦注射液制備工藝研究、質(zhì)量控制和穩(wěn)定性研究》下載
已經(jīng)有1人回復(fù)
-
26申博自薦
已經(jīng)有12人回復(fù)
相關(guān)版塊跳轉(zhuǎn)
我要訂閱樓主 ienjoysun 的主題更新
| 1 | 1/1 | 返回列表 |
| 最具人氣熱帖推薦 [查看全部] | 作者 | 回/看 | 最后發(fā)表 | |
|---|---|---|---|---|
|
[考研] 317分 一志愿南理工材料工程 本科湖工大 求調(diào)劑 +6 | 芋泥小鈴鐺 2026-03-28 | 6/300 |
|
|---|---|---|---|---|
|
[考研] 322求調(diào)劑 +5 | 舊吢 2026-03-24 | 5/250 |
|
|
|
[考研] 349求調(diào)劑 +6 | 杰斯塔里斯 2026-03-21 | 6/300 |
|
|
|
[考研] 291求調(diào)劑 +15 | hhhhxn.. 2026-03-23 | 21/1050 |
|
|
|
[考研] 339求調(diào)劑 +6 | 烤麥芽 2026-03-27 | 8/400 |
|
|
|
[考研] 311求調(diào)劑 +3 | 希望上岸阿小楊 2026-03-23 | 3/150 |
|
|
|
[考研] 266分求材料化工冶金礦業(yè)等專業(yè)的調(diào)劑 +4 | 哇呼哼呼哼 2026-03-26 | 4/200 |
|
|
|
[考研] 安徽大學(xué)專碩生物與醫(yī)藥專業(yè)(086000)324分，英語(yǔ)已過(guò)四六級(jí)，六級(jí)521，求調(diào)劑 +4 | 美味可樂(lè)雞翅 2026-03-26 | 4/200 |
|
|
|
[考研] 一志愿陜師大生物學(xué)071000，298分，求調(diào)劑 +5 | SYA！ 2026-03-23 | 5/250 |
|
|
|
[考研] 324求調(diào)劑 +8 | hanamiko 2026-03-26 | 10/500 |
|
|
|
[考研] 調(diào)劑求收留 +7 | 果然有我 2026-03-26 | 7/350 |
|
|
|
[考研] 一志愿天津大學(xué)339材料與化工求調(diào)劑 +3 | 江往賣魚 2026-03-26 | 3/150 |
|
|
|
[考研] 334分 一志愿武理-080500 材料求調(diào)劑 +4 | 李李不服輸 2026-03-25 | 4/200 |
|
|
|
[考研] 求調(diào)劑 +3 | 李李不服輸 2026-03-25 | 3/150 |
|
|
|
[考研] 一志愿武理085500機(jī)械專業(yè)總分300求調(diào)劑 +3 | an10101 2026-03-24 | 7/350 |
|
|
|
[基金申請(qǐng)] 請(qǐng)教下大家 2026年國(guó)家基金申請(qǐng)是雙盲審嗎？ +3 | lishucheng1 2026-03-22 | 5/250 |
|
|
|
[考研] 328求調(diào)劑 +4 | LHHL66 2026-03-23 | 4/200 |
|
|
|
[考研] 293求調(diào)劑 +3 | 濤濤Wjt 2026-03-22 | 5/250 |
|
|
|
[考研] 308求調(diào)劑 +3 | 墨墨漠 2026-03-21 | 3/150 |
|
|
|
[考研] 275求調(diào)劑 +6 | shansx 2026-03-22 | 8/400 |
|